Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 319-325

  Nakaya, Takaaki ^a   Iwai, Shigenori ^a   Fujinaga, Koh ^a   Sato, Yuriko ^a   Otsuka, Eiko ^a   Ikuta, Kazuyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OLIGONUCLEOTIDE; REV PROTEIN; RNA; TRANSACTIVATOR PROTEIN;

ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY; ENVELOPE GENE; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RNA SYNTHESIS; TRANSACTIVATION; VIRUS REPLICATION;

EID: 0031039714     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.319     Document Type: Article

References (64)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Baltimore, D. 1988. Intracellular immunization. Nature (London) 335:395-396.
3. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vesinet-Brun, C. Rozioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
4. Bartel, D., M. Zapp, M. Green, and J. Szostak. 1991. HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell 67:529-536.
5. Berger, J., C. Aepinus, M. Dobrovnik, B. Fleckenstein, J. Hauber, and E. Böhnlein. 1991. Mutational analysis of functional domain in the HIV-1 Rev trans-regulatory protein. Virology 183:630-635.
6. Bevec, D., M. Dobrovnik, J. Hauber, and E. Böhnlein. 1992. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc. Natl. Acad. Sci. USA 89:9870-9874.
7. Bielinska, A., R. A. Shivdasani, L. Zhang, and G. J. Nabel. 1990. Regulation of gene expression with double-stranded phosphorothioate oligonucleotidcs. Science 250:997-1000.
8. Cao, Y., D. D. Ho, J. Todd, R. Kokka, M. Urdea, J. D. Lifson, M. Piatak, Jr., S. Chen, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retroviruses 11:353-361.
9. Chang, D. D., and P. A. Sharp. 1989. Regulation by HIV Rev depends upon recognition of splice sites. Cell 59:789-795.
10. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, P. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:431-438.
11. Clusel, C., E. Ugarte, N. Enjolras, M. Vasseur, and M. Blumenfeld. 1993. Ex vivo regulation of specific gene expression by nanomolar concentration of double-stranded dumbbell oligonucleotides. Nucleic Acids Res. 21:3405-3411.
12. Cullen, B. R. 1993. Does HIV-1 Tat induce a change in viral initiation rights? Cell 73:417-420.
13. Cullen, B. R., and W. C. Greene. 1989. Regulatory pathways governing HIV-1 replication. Cell 58:423-426.
14. Emerman, M., R. Vazeux, and K. Peden. 1989. The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization. Cell 57:1155-1165.
15. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N. Pavlakis. 1989. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86:1495-1499.
16. Fenster, S. D., R. W. Wagner, B. C. Froehler, and D. J. Chin. 1994. Inhibition of human immunodeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for Rev-responsive element stem-loop. V. Biochemistry 33:8391-8398.
17. Fischer, U., S. Meyer, M. Teufel, C. Heckel, R. Lührmann, and G. Rautmann. 1994. Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA. EMBO J. 13:4105-4112.
18. Fujinaga, K., Q. Zhong, T. Nakaya, M. Kameoka, T. Meguro, K. Yamada, and K. Ikuta. 1995. Extracellular Nef protein regulates productive HIV-1 infection from latency. J. Immunol. 155:5289-5298.
19. Gait, M. J., and J. Karn. 1993. RNA recognition by the human immunodeficiency virus Tat and Rev proteins. Trends Biochem. Sci. 18:255-259.
20. Gilboa, E., and C. Smith. 1994. Gene therapy for infectious diseases: the AIDS model. Trends Genet. 10:139-144.
21. Graham, G. J., and J. J. Maio. 1990. RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral transactivator. Proc. Natl. Acad. Sci. USA 87:5817-5821.
22. Heaphy, S., J. T. Finch, M. J. Gait, J. Karn, and M. Singh. 1991. Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich "bubble" located within the rev-responsive region of viral mRNAs. Proc. Natl. Acad. Sci. USA 88:7366-7370.
23. Hope, T. J., N. P. Klein, M. E. Elder, and T. G. Parslow. 1992. trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes. J. Virol. 66:1849-1855.
24. Hsu, M.-C., A. D. Schutt, M. Holly, L. W. Slice, M. I. Sherman, D. D. Richman, M. J. Potash, and D. J. Volsky. 1991. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 254: 1799-1802.
25. Ikuta, K., C. Morita, S. Miyake, T. Ito, M. Okabayashi, K. Sano, M. Nakai, K. Hirai, and S. Kato. 1989. Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens. Virology 170:408-417.
26. Iwai, S., C. Pritchard, D. A. Mann, J. Karn, and M. J. Gait. 1992. Recognition of the high affinity binding site in rev-responsive element RNA by the human immunodeficiency virus type-1 rev protein. Nucleic Acids Res. 20: 6465-6472.
27. Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
28. Kikukawa, R., Y. Koyanagi, S. Harada, N. Kobayashi, M. Hatanaka, and N. Yamamoto. 1986. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J. Virol. 57:1159-1162.
29. Kishi, M., Y. Nishino, K. Ohki, T. Kimura, and K. Ikuta. 1993. Persistently human immunodeficiency virus type 1-infected T cell clone expressing only doubly spliced mRNA exhibits reduced cell surface CD4 expression. Jpn. J. Cancer Res. 84:153-162.
30. Kjems, J., A. D. Frankel, and P. A. Sharp. 1991. Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. Cell 67:169-178.
31. Kjems, J., and P. A. Sharp. 1993. The basic domain of Rev from human immunodeficiency virus type 1 specifically blocks the entry of U4/U6-U5 small nuclear ribonucleoprotein in spliceosome assembly. J. Virol. 67:4769-4776.
32. Lee, S. W., H. F. Gallardo, E. Gilboa, and C. Smith. 1994. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev responsive element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol. 68:8254-8264.
33. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1992. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol. 4:66-74.
34. Li, G., J. Lisziewicz, D. Sun, G. Zon, S. Daefler, F. Wong-Staal, R. C. Gallo, and M. E. Klotman. 1993. Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligonucleotide phosphorothioate analogs directed against the Rev-responsive element. J. Virol. 67:6882-6888.
35. Lisziewicz, J., D. Sun, M. Klotman, S. Agrawal, and P. Zamecnik. 1992. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc. Natl. Acad. Sci. USA 89:11209-11213.
36. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reiz, and R. C. Gallo. 1993. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. USA 90:8000-8004.
37. Liu, J., C. Woffendin, Z.-Y. Yang, and G. Nabel. 1994. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Ther. 1:32-37.
38. Malim, M. H., S. Böhnlein, J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 Rev trans-activator: derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
39. Malim, M. H., and B. R. Cullen. 1991. HIV-1 structural gene expression requires the binding of multiple monomers to the viral RRE: implications for HIV-1 latency. Cell 65:241-248.
40. Malim, M. H., and B. R. Cullen. 1993. Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol. Cell. Biol. 13:6180-6189.
41. Malim, M. H., J. Hauber, S.-Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature (London) 338:254-257.
42. Malim, M. H., D. F. McCarn, L. S. Tiley, and B. R. Cullen. 1991. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 65:4248-4254.
43. Mann, D. A., I. Mikaelian, R. W. Zemmel, S. M. Green, A. D. Lowe, T. Kimura, M. Singh, P. J. G. Butler, M. J. Gait, and J. Karn. 1994. Cooperative Rev binding to stem I of the Rev-responsive element modulates human immunodeficiency virus type-1 late gene expression. J. Mol. Biol. 241:193-207.
44. Mermer, B., B. K. Felber, M. Campbell, and G. N. Pavlakis, 1990. Identification of trans-dominant HIV-1 Rev protein mutants by direct transfer of bacterially produced proteins into human cells. Nucleic Acids Res. 18:2037-2044.
45. Meyer, B. E., and M. H. Malim. 1994. The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Gene Dev. 8:1538-1547.
46. Minowada, J., T. Ohnuma, and G. E. Moore. 1972. Rosette forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J. Natl. Cancer Inst. 49:891-895.
47. Miyoshi, I., H. Taguchi, I. Kubonishi, S. Yoshimoto, Y. Ohtsuki, Y. Shiraishi, and T. Akagi. 1982. Type C virus producing cell lines derived from adult T cell leukemia, p. 219-228. In H. Hanaoka, K. Takatsuki, and M. Shimoyama (ed.), Adult T cell leukemia and related disease. GANN Monograph on Cancer Research no. 28. Japan Scientific Societies Press, Tokyo.
48. Modesti, N., J. Garcia, C. Debouck, M. Peterlin, and R. Gaynor. 1991. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol. 3:759-768.
49. Nishino, Y., T. Nakaya, K. Fujinaga, M. Kishi, I. Azuma, and K. Ikuta. 1994. Persistent infection of MT-4 cells by human immunodeficiency virus type 1 becomes increasingly likely with in vitro serial passage of wild-type but not nef mutant virus. J. Gen. Virol. 75:2241-2251.
50. Pearson, L., J. Garcia, F. Wu, N. Modesti, J. Nelson, and R. Gaynor. 1990. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc. Natl. Acad. Sci. USA 87:5079-5083.
51. Perelson, A. S., A. U. Neuman, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
52. Richard, N., S. Iacampo, and A. Cochrane. 1994. HIV-1 Rev is capable of shuttling between the nucleus and cytoplasm. Virology 204:123-131.
53. Shukla, R., P. Kimmel, and A. Kumar. 1994. Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins. J. Virol. 68:2224-2229.
54. Stutz, F., and M. Rosbash. 1994. A functional interaction between Rev and yeast pre-mRNA is related to splicing complex formation. EMBO J. 13: 4096-4104.
55. Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608.
56. Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65:6811-6816.
57. Symensma, T. L., L. Giver, M. Zapp, G. B. Takle, and A. D. Ellington. 1996. RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J. Virol. 70:179-187.
58. Tanaka, H., P. Vickart, J.-R. Bertrand, B. Rayner, F. Morvan, J.-L. Imbach, D. Paulin, and C. Malvy. 1994. Sequence-specific interaction of α · β-anomeric double-stranded DNA with the p50 subunit of NF-κB: application to the decoy approach. Nucleic Acids Res. 22:3069-3074.
59. Vaishnav, Y., M. Vaishnav, and F. Wong-Staal. 1991. Identification and characterization of a nuclear factor that specifically binds to the Rev response element (RRE) of human immunodeficiency virus type 1 (HIV-1). New Biol. 3:142-150.
60. Venkatesh, L. K., and G. Chinnadurai. 1990. Mutants in a conserved region near the carboxy-terminus of HIV-1 Rev identify functionally important residues and exhibit a dominant negative phenotype. Virology 178:327-330.
61. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.
62. Yu, M., E. Poeschla, and F. Wong-Staal. 1994. Progress towards gene therapy for HIV infections. Gene Ther. 1:13-26.
63. Yunoki, M., K. Maotani-Imai, H. Kusuda, M. Motoyama, S. Miyake, H. Imai, Y. S. Shin, S. Kato, K. Sano, C. Morita, M. Nakai, K. Hirai, and K. Ikuta. 1991. Production of infectious particles from detective human immunodeficiency virus type 1 (HIV-1)-producing cell clones by superinfection with infectious HIV-1. Arch. Virol. 116:143-158.
64. Zapp, M. L., S. Stern, and M. R. Green. 1993. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74:969-978.